Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

J. P. Wijnen, L. Jiang, T. R. Greenwood, M. Cheng, M. Döpkens, M. D. Cao, Z. M. Bhujwalla, B. Krishnamachary, D. W.J. Klomp, K. Glunde

Research output: Contribution to journalArticlepeer-review

Abstract

Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (31P) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors.

Original languageEnglish (US)
Pages (from-to)692-699
Number of pages8
JournalNMR in biomedicine
Volume27
Issue number6
DOIs
StatePublished - Jun 2014

Keywords

  • Breast cancer
  • GDPD5
  • Glycerophosphoesterdiesterase
  • In vivo
  • Metabolism
  • Silencing

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Spectroscopy

Fingerprint

Dive into the research topics of 'Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by <sup>31</sup>P MRS'. Together they form a unique fingerprint.

Cite this